#SFHS2607212AFrance Adds ZIEXTENZO to Hospital Add-On Reimbursement List
AI-generated summary for informational purposes only. Not legal advice. See the original source for the authoritative text.
This order adds ZIEXTENZO, a pegfilgrastim injectable medicine from Sandoz, to the list of drugs that can be billed separately from standard hospital services in France. The extra reimbursement applies only for reducing the duration of neutropenia and the incidence of febrile neutropenia in adult cancer patients receiving cytotoxic chemotherapy, excluding chronic myeloid leukemia and myelodysplastic syndromes. Hospitals, oncology departments, payers, and Sandoz are the main affected parties.
AI-generated summary. May contain errors. Refer to official sources for legal decisions.
Key Changes
- Adds ZIEXTENZO 6 mg pre-filled syringe to the hospital add-on reimbursement list
- Limits reimbursement to a specific oncology-related indication involving chemotherapy-induced neutropenia
- Identifies Sandoz as the marketing authorization holder or operating laboratory
Obligations
What this law requires
Hospitals may bill ZIEXTENZO 6 mg pegfilgrastim injectable solution in prefilled syringe, UCD code 3400894431305, separately from standard hospitalization services only under the reimbursement list referenced in Article L. 162-23-6 of the Social Security Code.
Separate reimbursement by health insurance for ZIEXTENZO is limited to reducing the duration of neutropenia and the incidence of febrile neutropenia in adult patients receiving cytotoxic chemotherapy for malignant disease.
Hospitals and payers must not treat ZIEXTENZO as eligible for separate reimbursement under this order for chronic myeloid leukemia or myelodysplastic syndromes, because those indications are expressly excluded.